Imlifidase
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Using the drug-repurposing evaluation report template supplied in the prompt to produce the Imlifidase report below.
Imlifidase: From Transplant Desensitisation (Unconfirmed) to Diabetic Cataract
One-Sentence Summary
Imlifidase (DrugBank DB15258) has no confirmed original indication in the current evidence pack — background knowledge suggests use as a pre-transplant IgG-degrading desensitisation agent, but this is not sourced from this dataset and requires manual verification. The TxGNN model predicts potential relevance to Diabetic Cataract, but this is supported by 0 clinical trials and 0 publications, and the model’s own rationale flags the result as possibly a knowledge-graph clustering artefact rather than a genuine pharmacological signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not established in this evidence pack — original_indications is empty and original_moa is flagged as a data gap |
| Predicted New Indication | Diabetic Cataract |
| TxGNN Prediction Score | 98.75% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for Imlifidase in this evidence pack (original_moa = data gap), and no original indication is recorded. Background pharmacological knowledge — not sourced from this dataset and requiring independent verification — describes Imlifidase as an IgG-degrading cysteine protease used for antibody desensitisation prior to organ transplantation in highly sensitised patients. This background is included here only because the model’s own repurposing rationale surfaces it; it should be confirmed against DrugBank/EMA/SmPC sources before being relied upon.
Critically, the model-generated rationale for this prediction is itself skeptical: it states that diabetic cataract pathology is driven by lens protein glycation, sorbitol-pathway accumulation, and oxidative stress — mechanisms with no known relationship to IgG cleavage or complement-mediated immune pathways. The rationale explicitly notes that the high TxGNN score may reflect a clustering artefact in the knowledge graph (disease nodes for various cataract subtypes embedding close together) rather than a true pharmacological signal.
This is reinforced by the structure of the ranked candidate list: 8 of the top 10 predictions are cataract subtypes/variants (diabetic, craniostenosis, mature, tetanic, immature, type-2-diabetes-associated) clustered at nearly identical scores (~98.7–98.75%), including exact duplicate entries. This pattern is consistent with an embedding-space artefact affecting a whole disease cluster, rather than a specific, differentiated biological hypothesis for Imlifidase. Given the absence of any mechanistic, preclinical, or clinical support, this prediction should be treated as exploratory only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Denmark Market Information
Imlifidase currently holds no marketing authorisation in Denmark (market_status: Not marketed; 0 registered licenses). No product, dosage form, or approved-indication data is available from Laegemiddelstyrelsen or EMA centralised records in this evidence pack.
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
(Note: no drug–drug interaction data was found; key warnings and contraindications are currently unavailable and are flagged as a blocking data gap — see Next Steps.)
Conclusion and Next Steps
Decision: Hold
Rationale:
- The prediction has no clinical trial or literature support (Evidence Level L5), and the model’s own mechanistic rationale casts doubt on biological plausibility, suggesting a possible graph-embedding artefact affecting an entire cataract-subtype cluster rather than a specific, credible hypothesis.
- Original indication and mechanism of action data are both missing from this evidence pack, and a Blocking-severity data gap (missing TFDA/local label warnings and contraindications) prevents even a preliminary (S1) safety assessment.
To proceed, the following is needed:
- Confirmed original indication and mechanism of action for Imlifidase (DG002, High severity — query DrugBank API)
- Local regulatory label warnings, contraindications, and safety data to clear the Blocking gap (DG001 — obtain and parse SmPC/label PDF)
- Independent pharmacological assessment of whether any plausible mechanistic link exists between IgG-degrading protease activity and diabetic cataract pathology
- Resolution of the duplicate/near-identical ranked candidates before this signal is considered distinct from a broader “cataract cluster” artefact
- If pursued further, preclinical or case-level evidence before any clinical investment is considered
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.